Form 4: Director Jonathan Freeman Acquires PHIO Stock

Phio Pharmaceuticals Director Jonathan Freeman acquired 16,600 shares of common stock in the form of restricted stock units, increasing his beneficial ownership to 32,655 shares.

Summary

• Jonathan E. Freeman, a Director of Phio Pharmaceuticals Corp. (PHIO), was granted 16,600 shares of common stock in the form of restricted stock units on February 5, 2026.
• These restricted stock units will vest on February 5, 2027, which is the first annual anniversary of the grant date.
• Following this grant, Mr. Freeman directly beneficially owns a total of 32,655 shares of common stock, which includes these newly granted unvested restricted stock units.
• The reported number of securities has been adjusted to account for prior reverse stock splits.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as the grant of restricted stock units aligns the director's interests with the company's long-term stock performance, a standard practice for incentivizing leadership.

Positives

• A director acquiring shares, even through a grant, can signal confidence in the company's future outlook.
• The grant of restricted stock units aligns the director's interests with long-term shareholder value through future vesting.

Negatives

• The acquisition was a grant with a price of $0, not an open market purchase, which might be viewed differently than a direct cash investment by the director.

Risks

• The value of the restricted stock units is directly tied to the future market performance of Phio Pharmaceuticals Corp. common stock.
• Unvested restricted stock units represent future compensation that is contingent on continued service and the company's performance.

Future Outlook

The filing indicates future vesting of 16,600 restricted stock units on February 5, 2027, aligning the director's future compensation with the company's stock performance.

Industry Context

StockSavvy.ai notes that insider grants of restricted stock units are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to incentivize long-term performance and retention. This practice aligns director interests with shareholder value, a standard governance practice.

Comparison to Industry Standards

• The grant of restricted stock units at a $0 price is standard practice for equity compensation, similar to grants observed at peer biotech companies like Moderna (MRNA) or BioNTech (BNTX) for their directors and executives.
• The vesting schedule of one year is a common short-to-medium term incentive structure, though longer vesting periods (e.g., 3-4 years) are also prevalent for broader executive compensation plans across the industry.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased director alignment with stock performance and long-term company success.
• Employees: No direct impact on employees is mentioned in this filing.

Next Steps

• Vesting of 16,600 restricted stock units on February 5, 2027.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice designed to align insider interests with shareholder value. While it indicates continued commitment from the director, it does not present new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment stance. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive corporate updates.

Keywords

Phio Pharmaceuticals, PHIO, Form 4, Insider Trading, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership